NK

NantKwest
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.890
+0.290
+11.15%
Opening 11:39 04/06 EDT
OPEN
2.700
PREV CLOSE
2.600
HIGH
2.890
LOW
2.670
VOLUME
323.64K
TURNOVER
--
52 WEEK HIGH
9.90
52 WEEK LOW
0.9500
MARKET CAP
284.62M
P/E (TTM)
-4.0900
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NK stock price target is 3.500 with a high estimate of 3.500 and a low estimate of 3.500.

EPS

NK News

More
  • NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
  • Business Wire · 03/19 13:00
  • NantKwest launches mid-stage study of NK cells in rare skin cancer
  • Seeking Alpha - Article · 03/19 12:27
  • SPCE, I, FLR and WWR among midday movers
  • Seeking Alpha - Article · 02/18 17:40
  • 70 Biggest Movers From Yesterday
  • Benzinga · 01/29 09:40

Industry

Biotechnology & Medical Research
+3.76%
Pharmaceuticals & Medical Research
+3.02%

Hot Stocks

Symbol
Price
%Change

About NK

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
More

Webull offers kinds of Nantkwest Inc stock information, including NASDAQ:NK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NK stock news, and many more online research tools to help you make informed decisions.